Belgium · Delayed Price · Currency is EUR Fagron NV Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 10.3% to €263 million, driven by LatAm and M&A, with EBITDA margin guidance at 20%. Integration of recent acquisitions is on track, and the outlook remains positive with mid to high single-digit organic growth expected.
Fiscal Year 2025
-
Revenue grew 9.2% to €952 million in 2025, with strong organic growth and margin expansion across all regions. Twelve acquisitions were announced, and integration is underway, while 2026 guidance calls for continued mid- to high single-digit growth and slight profitability improvement.
-
Normalized organic growth reached 8.5% in Q3, with full-year revenue guidance reaffirmed at EUR 930–950 million and profitability set to improve. Eight acquisitions and major capacity expansions support global growth, while EMEA and North America delivered strong segment results.
-
H1 2025 saw 11.3% organic revenue growth, margin expansion to 20%, and strong performance across all regions, led by North America and LATAM. Four acquisitions expanded the global footprint, and guidance remains for mid to high single-digit organic growth and improved profitability.
-
Management targets high single- to low double-digit organic growth through 2030, driven by operational excellence, innovation, and disciplined M&A, with EBITDA margin rising to 21% by 2027. Major CapEx projects expand capacity, while quality, regional growth, and brand strategy remain central to long-term value creation.
Fiscal Year 2024
-
Revenue grew 16.8% year-on-year to EUR 872 million, with margin up to 20% and strong cash flow conversion. North America led growth, driven by compounding services and GLP-1 drug shortages, while EMEA and LatAm showed resilience. Six acquisitions support ongoing market consolidation and portfolio expansion.
-
Nine-month organic revenue grew 12.6% at CER, with all regions contributing and three acquisitions announced. Full-year revenue guidance is reaffirmed at EUR 850–870 million, with profitability set to improve year-on-year despite FX headwinds and ongoing integration of recent deals.
-
Strong H1 2024 results with 12.8% organic growth at CER and revenue of EUR 429 million, led by North America and Compounding Services. Upgraded full-year guidance to EUR 850–870 million, with margin improvement and major investments in capacity expansion in the U.S. and Netherlands.